Isolation, Characterization and Myogenic Differentiation of Synovial Mesenchymal Stem Cells

Fatma Yassine Meligy, Dalia Abdo Elgamal, Nashwa Ahmed Mohamed Mostafa, Ayat sayed Abdelrahman

1 Histology and cell biology Department, Faculty of Medicine, Assiut University, Assiut, Egypt
2 Medical Biochemistry Department, Faculty of Medicine, Assiut University, Assiut, Egypt

ABSTRACT

Background: Synovial membrane represents a worthy source of mesenchymal stem cells (MSCs). Synovial membrane derived stem cells has been described as encouraging line of treatment for musculoskeletal degenerative disorders compared to other sources MSCs. Having higher chondrogenic capacity and being easy to collect without injury of adjacent tissue as well as its proximity to the articular cartilage make it good choice for treatment of such disorders.

Aim of work: The present study aimed to isolate and characterize (MSCs) derived from synovial membrane and to examine its myogenic differentiation potential.

Materials and Methods: Four adult mice were used to isolate synovial membrane MSCs using digestion method, after which, 5 –azacytidine (AZA) was used to induce the myogenic differentiation. Stemness and differentiation characteristics were evaluated by immunocytochemistry (ICC), fluorescence-activated cell sorting (FACS) and real time PCR.

Results: Strong positive expression of CD29, CD44, CD90 and CD105 and negative expression of CD34 and CD45 were reported for MSCs using ICC. Also, FACS analysis showed 92%, 86%, 93% and 90% for CD29, CD44, CD90 and CD105 expressing cells respectively. On the other hand AZA treated cells showed strong desmin and myogen expression (80%).

Conclusion: Synovial mesenchymal MSCs could be expanded in vitro and differentiated towards myogenic lineage which is promising treatment strategies in musculoskeletal diseases.

Key Words: Mesenchymal stem cells, myogenic differentiation, synovium.

INTRODUCTION

Stem cells gained consideration due to their recent use in cell-based therapy in different diseases due to their significant proliferative and differentiation capacities towards various tissue lineages irrespective of their origin. At present, most scientific researches cell based therapy are devoted to development of protocols, preliminary for clinical utilization. Adult stem cells, as particularly MSC have been originally isolated from bone marrow. Also, they have been retrieved from variety of adult tissues such as muscle, dermis, adipose tissue and recently synovial membrane.

The synovial membrane is a tissue that lines the joint cavity of synovial joints and consists of a lining layer of macrophage-like (type A) and fibroblast-like (type B) synoviocytes and a loose sublining tissue.

Proliferation of synoviocytes, fibroblast-like (type B) subsidizes to synovial hyperplasia in response to damage or trauma. Accumulated evidence suggested that adult synovial membrane harbors cells that behave like multipotent mesenchymal/stromal stem cells (MSCs) after release and culture expansion. Rat Synovial MSCs showed high proliferative potential compared to adipose tissue, bone-marrow, periosteum and muscle-derived stem cells as shown by higher colony number per each adherent nucleated cell, and cell number per colony.

The properties of MSCs can be affected by their preparation as well as by their origin; for instance, stem cells from bone marrow or synovium may better differentiate into chondrogenic and osteogenic lines. Hence, the choice of an appropriate stem cell source may also play central role in efficiency of development of a specific tissue regeneration paradigm. For example, Satellite cells showed higher ability to restore functional muscle tissue being of same origin tissue. However, because of lack of differentiation of these Satellite cells in higher passages, MSCs were developed as a therapeutic strategy in musculoskeletal diseases. MSCs derived from human synovial membrane can restore damaged muscle. Although, synovial MSCs were known for their high chondrogenic as well as calcification and adipogenic potentials their myogenic differentiation potential have not been well explored.
So, the aim of our study is to isolate MSCs from synovial membrane and to differentiate these stem cells into skeletal myocytes in vitro.

**MATERIALS & METHODS**

**Animals:**

Institutional Animal Care and Use Committee of Assiut University, Faculty of Medicine approved all procedures dealt with mice. Four adult eight-week-old male mice were used in this study as donor animals for establishment of synovial mesenchymal cell culture.

Isolation of synovial MSCs: Primary cells were isolated through excision of the synovial membranes of bilateral knee joints. The tissues were minced, digested for 3 h at 37°C with type II collagenase (0.2%; Sigma, Lakewood, N.J., USA) followed by filtration through a 40μM mesh (Becton Dickinson, Franklin Lakes, N.J., USA) to yield single-cell suspensions. Phosphate-buffered saline solution (PBS) was added followed by two rounds of five min centrifugation at 1,500Xg to eliminate collagenase.

Culture and expansion of synovial MSCs: The liquid fraction containing the cells was centrifuged, rinsed twice with Dulbecco's modified Eagle's medium (DMEM) and resuspended in complete culture medium containing Alpha MEM media (Alpha modification of minimal essential medium Eagle) (Biochrom; AG, Berlin, Germany) supplemented with 20% (v/v) fetal bovine serum (FBS) (GIBCO BRL) and 1% (v/v) antibiotic/antimycotic solution. Isolated cells were plated into flasks and allowed to become adherent.

Detached cells were eliminated by changing the medium every 2 days. The cells were allowed to reach 80% confluence (3 days), after which they were rinsed with serum free DMEM, treated with trypsin-EDTA (GIBCO BRL) for 5 min, washed with DMEM twice, then subcultured in complete DMEM at a density of 2.0 × 10^5 cells/75 cm^2 dish.

**Myogenic differentiation:**

Ten mmol /l DMEM of 5-Azacytidine (AZA) (Sigma Chemical) were added to 50,000 cells of passage 2 synovial MSCs with 10% FBS and 5% DHS (Donor horse serum, BiochromAG), and incubated for 24 hours at 37°C and 5% CO2. Untreated cells were considered as controls. The cells were maintained in culture for 28 days. The control stem cells and AZA-treated cells were subsequently analyzed by Fluorescein activated cell sorting (FACS), Immunocytochemistry (ICC) and quantitative polymerase chain reaction (q-PCR) to assess stem cell surface and myogenic markers expression.

**Immunocytofluorescence staining:**

The cells of the isolated control and treated group were plated in chamber slides and cultured at 37°C, 5%CO2 humidified incubator. After 25- days, the medium was discarded; cells were washed twice with PBS and then fixed in 3% paraformaldehyde (PFA) in PBS for 20 min at 37C. PFA was removed and cells were washed three times with 0.1% Triton X-100 in PBS and incubated for 15 min at 37°C. Cells were incubated for 30 min at 37°C with 2% bovine serum albumin (BSA) in PBS to block non specific antigen on the cell surface. Diluted primary antibodies were added to the fixed and blocked cells. The cells were then incubated overnight at 4°C with primary antibodies diluted in blocking solution. The following primary antibodies; mouse monoclonal antibodies against CD90, CD 29, CD44 (HCAM), CD45, CD 105 and CD34 (1:200; Santa Cruz Biotechnology, Santa Cruz, CA USA) and rabbit monoclonal antibody against Desmin (1:200; Abcam, Cambridge, UK).

After washing, the cells were mixed with secondary antibody (Alexa Fluor 647)(Invitrogen, CA, USA) and incubated for another 30 min on ice. Cells were co-stained with DAPI (1:500; 4', 6-diamidino-2-phenylindole; Molecular Probes, Eugene, OR) to visualize the nuclei. Finally, Stained cells were mounted with fluoroscent mounting medium (Dako, Carpinteria, CA). Skeletal muscle from mice served as positive control for all ICC staining. In each group, an isotope control was performed using mouse-IgG1 (Becton Dickinson, San Jose, CA) instead of the primary antibody. The fluorescent images were analyzed and obtained by a fluorescent microscope (Olympus microscope BX51, Japan).

**Flow cytometry.**

Cultured isolated control stem cells and AZA treated cells were analyzed using FACS (cell analyzer) (Becton Dickinson Biosciences, Bedford, MA, USA). Cells were suspended in 500 μl PBS containing 20 ng/ml fluorescein isothiocyanate (FITC)-coupled antibodies against CD90, CD45, CD44, CD 29, CD34, (Santa Cruz Biotechnology), CD105 (Endoglin) (Dako Cytomation, Carpinteria, CA) and myogenin (mouse monoclonal, Becton Dickinson Franklin Lakes, N.J., USA), or as an isotype control, FITC-coupled nonspecific IgG (Becton Dickinson). After washing, the cells were incubated for another 30 min away from light on ice with Alexa Fluor 647 (Santa Cruz Biotechnology) as a secondary antibody. Then, the cells were washed twice and resuspended in 1 ml PBS for analysis.

**RNA extraction and real-time PCR analysis:**

RNA extraction and real-time PCR analysis: Total RNA was extracted from cells and purified using Trizol reagent (Invitrogen, Carlsbad, CA) in accordance with the manufacturer’s protocol (Invitrogen, Carlsbad, CA). High Capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA, USA) was used to synthesize the 1st strand cDNA from50μg of total RNA and random hexamer. Real-time RT-PCR was performed in a StepOne™ real time PCR System (Applied BioSystems) using syber green for desmin and b actin as an internal
control. The following primers were used, desmin forward primer 5'-TACACCTGCGAGATTGATGC-3', desmin reverse primer: 5'-GTAGCCTCGCTGACAACCTC-3', and B-actin primer as an internal control, forward 5'-GGACTTCGAGCAAGAGATGG-3 and reverse 5'-AGCACTGTGTGGCGTACAG-3.

Statistical analysis of the data: Statistical significant differences between the two groups were determined using Student's t test. All data are presented as mean± SD is an index of the variability of the original data points. Statistical significance was set at P<0.05.

RESULTS:

Microscopic cell morphology:

Synovial membrane derived Stem cells were plastic-adherent and demonstrated characteristic spindle-shaped and fibroblast-like morphology. The cells reach 80% confluence in one week (Fig. 1).

After induction of differentiation, the cells were observed every 2 days for 28 days, the cells were analyzed with fluorescence and inverted microscopy to evaluate the growth and myogenic differentiation of both groups.

Phenotypic characterization & Immunocytochemistry

Synovial membrane derived MSCs. showed high expression of CD29, CD44, CD90, and CD105 surface markers (Fig.2A,B,C,D), while the immunophenotypes were noted negative for CD34 and CD45; markers of hematopoietic progenitors and endothelial cells respectively(Fig. 2 E and F). As expected synovial membrane derived MSCs expressed weak desmin (Fig. 3a). Interestingly, the AZA-treated cells showed strong expression of desmin protein (Fig 3b).

Fluorescence-activated cell sorting analysis

Flowcytometric analysis of synovial membrane derived mesenchymal cells demonstrated positive expression for CD29, CD44, CD 90 and CD105 (Fig 4a: B, C, D, E) and negative expression for CD34 and CD 45 (Fig.4a: F and G). The percentage of CD29, CD44, CD 90 and CD105- positive-expressing cells was 92%, 86%, 93% and 90% respectively. In addition, myogenin expression was statically higher in AZA-treated MSCs (T) (80%) compared to the untreated synovial derived -MSCs(C) (12%) (Fig.4b: b).

Reverse transcription polymerase chain reaction

Desmin expression was detected weekly in myogenic differentiated cells throughout observation period by PCR analysis (unpublished results). However, Desmin expression in AZA-treated cells was higher than that

Fig.1 Growth morphology of isolated MSCs derived from the synovial membrane. They are spindle in shape and fibroblast like.
ISOLATION AND MYOGENIC DIFFERENTIATION OF SYNOVIAL STEM CELLS

Fig. 2 Immunofluorescence staining for merged DAPI stained nuclei (blue); CD 29, CD 44, CD 90, CD 105, CD 34, CD 45, secondary antibody is Alexa Flour 647 (red), in isolated MSCs derived from synovial membrane were evaluated by fluorescent microscope. In (A-D) MSCs relevant to CD29, CD 44, CD 90 and CD 105 positive expression are detected respectively. However, In (E-F) MSCs relevant to CD 34, CD 45 negative expressions are detected, respectively.

Fig. 3 Immunofluorescence staining for merged DAPI-stained nuclei (blue) and desmin-Alexa Flour 647(red) were evaluated by inverted microscopy. In (a), weak expression of desmin in the cytoplasm of few control untreated MSCs, While in (b), significant positive expression of desmin in the cytoplasm of treated MSCs derived from synovial membrane, were detected 4wk after induction of differentiation.

Fig. 4a Expression of MSCs surface markers are measured by flowcytometry in MSCs derived from synovial membrane. (a) Representative plot of IgG matched isotope (plot; A), CD29 (plot; B), CD44 (plot; C), CD90 (plot; D), CD105 (plot; E) CD34 (plot; F) and CD45 (plot G).
Fig. 4b Expression of striated muscle marker myogenin was measured by flowcytometry in SM-MSCs and in 5-azacytidine-treated SM-MSCs after induction of myogenic differentiation. (a) Representative plot of IgG2b Isotope. (b) Representative of myogenin expression after 7 days in control (C) and in 5-azacytidine treated SD-MSCs (T).

Fig. 5a Expression of striated muscle marker desmin in untreated and 5-azacytidine-treated MSCs derived from synovial membrane 4 weeks after induction of myogenic differentiation. Representative PCR analysis of desmin and β-actin mRNA expression in untreated (lane 1) and 5-azacytidine-treated (lane 2)MSCs derived from synovial membrane.
DISCUSSION

Neuromuscular disease encompasses both intrinsic muscle pathology and nerve pathology distorting the function of the muscles. Currently, gene and cell therapy are recognized as putative treatment strategies for such neuromuscular diseases. In this study, we examined the potential of mice synovial membrane derived mesenchymal stem cells (SM-MSCs) to undergo myogenic differentiation in vitro. Morphology, mRNA and protein markers were investigated to show the true myogenic differentiation.

It is particularly noteworthy that the synovium has a high regenerative capacity, and it is easy to be obtained arthroscopically with minimal invasiveness. Besides, a least amount of synovium is sufficient to extract the MSCs successfully. Synovial membrane-derived cells were known to have the highest chondrogenic potential that last after many passages, employing pluripotent character of the synoviocytes. These pluripotent synoviocyte scan be isolated and expanded ex vivo, thereby providing a unique and accessible population of pluripotent cells from an unexpected tissue resource. Little is known about immunophenotypic, structural properties of these cells. Therefore, phenotypic and myogenic differentiation features of these cells were investigated in this study.

In this study, we were able to isolate SM-MSCs from synovial membrane of mice using the enzyme digestion method. Cells were cultured and purified by their adherent ability, colony formation and uniform morphology. In vitro cultivated SM-MSCs expressed cell-surface markers according to the criteria reported by Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy including CD29, CD44, CD90 and CD105. SM-MSCs cells were also lacking the expression of CD34 and CD45, a cell-surface marker associated with lymphohematopoietic cells as shown by both FACS and ICC. These results indicated the high self-renewal capacity of the synovium-derived MSCs in both rat and human. Also it have noted that these cells still hold the same kinetics of growth up to passages.

To further show the myogenic potential different ion of the SM-MSCs, AZA were added for 24 h and the expression of myoblast markers myogenin and desmin were analyzed weekly until day 28 from induction of differentiation.
According to the FACS analysis, the expression peak of skeletal muscle marker myogenin was at the end of first week where it reached 80% in differentiated SM-MSCs. After which myogenin expression decreased. This pattern of myogenin expression in SM-MSCs was similar to BM-MSCs. Zammit, 2017 had stated that myogenogenesis is regulated by a group of transcription factors as MyoD and Myf5 and myogenin, where MyoD and Myf5 are involved in the establishment of the skeletal muscle lineage while myogenin is required for fusion and terminal differentiation. So, myogenin is expressed in late period of myogenic differentiation, and this explain the peak of myogenin at 7 d followed by plateau levels of mature muscle markers.

In the meantime, expression of desmin in AZA-treated cells was higher than that in untreated control cells but the peak was at the 28th d. Expression of muscle-specific desmin with an up-regulation of this key initial transcription factor is characteristic in myoblasts and myocytes as muscle-specific marker gene and it is common to be used to detect cells with myogenic potential. Expression of specific skeletal muscle markers such as desmin, alfa-actin, sarcomeric actin and myogenin appeared following trans-differentiation process. Moreover, a previous study showed that early implanted human SM-MSCs in a model of muscle injury persisted within the regenerated muscle as quiescent satellite cells. Therefore, it has been proved that human SM-MSCs can participate in skeletal muscle regeneration in vivo by long term persistence and contribution to both myofibers and functional satellite cells.

Mogenic differentiation of human SM-MSCs have been characterized in an in vivo model of skeletal muscle regeneration and provided evidence of their capacity to partially restore specific pathophysiologic features of the dystrophic muscle in the mdx mouse model of muscle dystrophy. Although similar results were observed when MSCs were harvested from bone marrow and co-cultured with muscle precursor cells, previous authors had questioned the role of AZA as there are some evidences that it slightly increases myogenic differentiation. They claimed that the strongest effect on MSCs differentiation had occurred by adding conditioned medium from muscle precursor cells.

The present data further supports previous findings that the Synovial mesenchymal stem cells could be expanded in vitro and induced to myogenic differentiation which appears to be a promising in treatment strategies in musculoskeletal diseases.

CONFLICT OF INTEREST

The authors have no conflict of interest.

References


5. Gao, Yuhua, Chunyu Bai, Hui Xiong, Qian Li, Zhiqiang Shan, Linsheng Huang, Yuehui Ma, and Weijun Guan. "Isolation and Characterization of Chicken Dermis-Derived Mesenchymal Stem/ Progenitor Cells." BioMed research international (2013), 626258.


ISOLATION AND MYOGENIC DIFFERENTIATION OF SYNOVIAL STEM CELLS

عزل والتوصيف والتمايز العضلي للخلايا الجذعية الميزنشيمية المستخلصه من الغشاء الزليلي

فاطمة ياسين مليجي - داليا عبده الجمل - نشوى أحمد محمد مصطفى - آيات سيد عبد الرحمن
قسم الكيمياء الحيويه - كلية الطب - جامعة أسيوط - مصر

ملخص البحث

الخلايا الجذعية: يمثل الغشاء الزليلي مصدرًا جيدًا للخلايا الجذعية الميزنشيمية. وقد وصفت الخلايا الجذعية المستمدة من الغشاء الزليلي بأنها طريقة واعدة لعلاج اضطرابات العضلات الهيكلية التدنسية مقارنة مع الخلايا الجذعية الميزنشيمية المستخلصه من مصادر أخرى. ويعتبر ذلك إلى درجة هذه الخلايا الفعالة في تكوين الغضروف و كذلك كونها سهلة الجمع دون إصابة الأنسجة المجاورة بالإضافة إلى قربها من الغضروف المفصلي يجعلها خيارًا جيدًا لعلاج مثل هذه الاضطرابات.

هدف البحث: هدفت الدراسة إلى عزل وتصنيع الخلايا الجذعية الميزنشيمية من الغشاء الزليلي وفحص إمكانات التمايز العضلي المواد والطرق. تم استخدام أربعة فئران بالغة لعزل الخلايا الجذعية الميزنشيمية من الغشاء الزليلي باستخدام طريقة الهضم، وبعد ذلك تم استخدام مادة azacytidine (AZA) على التمايز العضلي. تم تقييم خصائص الجذعية والتمايز بواسطة طريقة كيمياء المناعة الخلوية، وجهاز تصنيف الخلايا المنشط بالوميض الفلورسنت (FACS) وتفاعل PCR.

نتائج البحث: أظهرت الخلايا الجذعية الميزنشيمية من الغشاء الزليلي تعبيراً إيجابياً قوياً لكلا من مضادات AZA و CD105 و CD90 و CD44 و CD90 و 29 و CD45 و 29 و 29 و 29 والموجهات L. تصلح فئران بالغة لعزل الخلايا الجذعية الميزنشيمية من الغشاء الزليلي. أظهرت الخلايا الجذعية الميزنشيمية المستخلصه من الغشاء الزليلي في المختبر ودفعت نحو التمايز العضلي والذي يعد من الاستراتيجيات العلاجية الواعدة في أمراض العضلات والظام.